Fulgent Genetics, Inc. (FLGT) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Fulgent Genetics, Inc. (FLGT) Healthcare & Pipeline Overview

Fulgent Genetics, Inc. delivers molecular diagnostic and genetic testing services, including oncology panels and COVID-19 tests, to healthcare providers and patients globally. The company distinguishes itself through comprehensive genetic testing solutions and strategic partnerships, operating in the competitive medical diagnostics market.

What Is the Investment Thesis for FLGT?

Fulgent Genetics operates in the growing molecular diagnostics and genetic testing market, with a market cap of $557M. Despite a negative profit margin of -23.0%, the company maintains a gross margin of 38.1%. Key value drivers include the expansion of its genetic testing services and strategic partnerships, such as the collaboration with Helio Health. Upcoming catalysts include the potential commercialization of early cancer detection tests. Potential risks include market competition and fluctuations in demand for COVID-19 testing, which could impact revenue streams. The company's beta of 0.89 suggests lower volatility compared to the broader market.

Based on FMP financials and quantitative analysis

FLGT Key Highlights

• Market Cap of $557M reflects Fulgent Genetics' current valuation in the market.
• Gross Margin of 38.1% indicates the profitability of Fulgent's core testing services.
• Profit Margin of -23.0% signals challenges in achieving overall profitability, potentially due to operating expenses or market conditions.
• Strategic partnership with Helio Health, Inc. aims to commercialize blood-based early cancer detection tests.
• Offers a comprehensive suite of genetic tests, including oncology panels and COVID-19 testing services.

Who Are FLGT's Competitors?

FLGT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are FLGT's Key Strengths?

• Comprehensive suite of genetic and diagnostic tests
• Strategic partnerships with healthcare providers and research institutions
• Advanced technology and expertise in next-generation sequencing
• Established customer base across various healthcare segments

What Are FLGT's Weaknesses?

• Negative profit margin
• Reliance on COVID-19 testing revenue
• Limited international presence
• High operating expenses

What Could Drive FLGT Stock Higher?

• Commercialization of blood-based early cancer detection tests in partnership with Helio Health, Inc.
• Expansion of genetic testing services for inherited conditions and oncology.
• Increased adoption of newborn genetic analysis panels.
• Geographic expansion into international markets.

What Are the Key Risks for FLGT?

• Negative return on equity (-6.7%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Insider selling — insiders were net sellers of roughly $1.6M recently.
• Intense competition from established diagnostic testing companies.
• Fluctuations in demand for COVID-19 testing.
• Regulatory changes and reimbursement pressures.
• Technological advancements rendering existing tests obsolete.
• Negative profit margin impacting financial stability.

What Are the Growth Opportunities for FLGT?

• Expansion of Oncology Testing Services: Fulgent Genetics can capitalize on the growing demand for personalized cancer treatment by expanding its oncology testing services. The global oncology market is projected to reach $286.6 billion by 2031, offering a substantial market opportunity. By developing more comprehensive and targeted oncology panels, Fulgent can attract a larger share of this market and improve patient outcomes. Timeline: Ongoing.
• Strategic Partnerships for Early Cancer Detection: The partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests represents a significant growth opportunity. Early cancer detection is a rapidly expanding field, driven by the potential to improve survival rates and reduce healthcare costs. Successful commercialization of these tests could generate substantial revenue for Fulgent. Timeline: Upcoming.
• Increased Adoption of Genetic Testing in Newborn Screening: Fulgent Genetics can leverage the increasing awareness and adoption of genetic testing in newborn screening programs. Early detection of genetic disorders can significantly improve outcomes for affected children. By expanding its newborn genetic analysis panel, Fulgent can tap into this growing market. Timeline: Ongoing.
• Geographic Expansion into International Markets: Expanding its services into international markets represents a significant growth opportunity for Fulgent Genetics. The global genetic testing market is expected to grow, and entering new regions can diversify revenue streams and reduce reliance on the US market. Focus on regions with increasing healthcare expenditure and awareness of genetic testing. Timeline: Ongoing.
• Development of Advanced Sequencing Technologies: Investing in the development and adoption of advanced sequencing technologies, such as long-read sequencing and single-cell sequencing, can enhance Fulgent Genetics' testing capabilities and attract new customers. These technologies offer improved accuracy and resolution, enabling the detection of rare and complex genetic variants. Timeline: Ongoing.

What Opportunities Does FLGT Have?

• Expansion of oncology testing services
• Commercialization of early cancer detection tests
• Increased adoption of genetic testing in newborn screening
• Geographic expansion into international markets

What Threats Does FLGT Face?

• Intense competition from established diagnostic testing companies
• Fluctuations in demand for COVID-19 testing
• Regulatory changes and reimbursement pressures
• Technological advancements rendering existing tests obsolete

What Are FLGT's Competitive Advantages?

• Comprehensive Test Menu: Offers a wide range of genetic and diagnostic tests, catering to diverse medical needs.
• Strategic Partnerships: Collaborations with companies like Helio Health, Inc. enhance its market reach and diagnostic capabilities.
• Advanced Technology: Utilizes next-generation sequencing and other advanced technologies for accurate and reliable testing.
• Established Customer Base: Serves a diverse clientele, including insurance companies, hospitals, and governmental bodies.

What Does FLGT Do?

Founded in 2011 and headquartered in Temple City, California, Fulgent Genetics, Inc. has evolved into a provider of molecular diagnostic and genetic testing services. Originally named Fulgent Diagnostics, Inc., the company rebranded in August 2016 to reflect its increasing focus on genetic testing. Fulgent's services include a comprehensive suite of genetic tests, such as Focus and Comprehensive oncology panels, Beacon carrier screening panels for inherited conditions, and solid tumor molecular profiling for somatic cancer testing. Additionally, Fulgent offers rapid whole genome testing for children in NICU and PICU, newborn genetic analysis panels, and single front-line tests to detect ataxia-related variants. The company also provides Picture Genetics, a patient-initiated genetic testing service, whole exome and clinical exome panel tests, and whole genome, mutation, and repeat expansion testing services, along with research service tests. Beyond genetic testing, Fulgent offers next-generation sequencing and reverse transcription polymerase chain reaction-based tests, as well as antigen-based diagnostic tests for SARS-CoV-2 detection. The company also provides flow cytometry, fluorescence in-situ hybridization, immunohistochemistry, cytogenetics, and molecular testing. Fulgent serves a diverse clientele, including insurance companies, hospitals, medical institutions, laboratories, governmental bodies, payors, municipalities, large corporations, and individual patients. A strategic partnership with Helio Health, Inc. aims to commercialize blood-based early cancer detection tests, enhancing Fulgent's market reach and diagnostic capabilities.

What Products and Services Does FLGT Offer?

• Provides molecular diagnostic testing services.
• Offers genetic testing for inherited conditions.
• Performs solid tumor molecular profiling for cancer testing.
• Conducts rapid whole genome testing for children in NICU and PICU.
• Offers newborn genetic analysis panels.
• Provides COVID-19 testing services.
• Offers flow cytometry and cytogenetics services.
• Provides research service tests.

How Does FLGT Make Money?

• Generates revenue through the sale of molecular diagnostic and genetic testing services.
• Partners with insurance companies, hospitals, and medical institutions to provide testing services.
• Offers direct-to-patient genetic testing services through Picture Genetics.
• Collaborates with other companies, such as Helio Health, Inc., to develop and commercialize new diagnostic tests.

What Industry Does FLGT Operate In?

Fulgent Genetics operates within the medical diagnostics and research industry, a sector characterized by rapid technological advancements and increasing demand for personalized medicine. The market is driven by the growing prevalence of genetic disorders and cancer, as well as advancements in sequencing technologies. Competition includes established players offering similar diagnostic services. Fulgent differentiates itself through its comprehensive test menu and strategic partnerships, positioning itself to capitalize on the expanding market for genetic testing.

Who Are FLGT's Key Customers?

• Insurance companies
• Hospitals and medical institutions
• Other laboratories
• Governmental bodies
• Individual patients

ROE -7%Key Financial Metrics

Return on equity for Fulgent Genetics, Inc. stands at -6.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -6.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -20.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.31 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -12.5%, the inverse of the P/E and a quick read on earnings relative to price.

Fulgent Genetics, Inc. (FLGT) Valuation Context

Valued at $557M, FLGT is classified as a small-cap stock. Relative to its peer group, FLGT's quantitative score of 39/100 is below the peer average of 66/100.

Company Profile

Fulgent Genetics, Inc. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in El Monte, US. The company is led by CEO Ming Hsieh. FLGT has traded publicly since 2016.

F-Score 2/9Financial Health

Fulgent Genetics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 4.12 places it in the safe zone, indicating low near-term bankruptcy risk.

FY2026 estForward Outlook

Wall Street analysts project Fulgent Genetics, Inc. revenue of about $352.2M for fiscal 2026, with EPS near $-1.55.

Net sellingInsider Activity

Over the past six months, Fulgent Genetics, Inc. insiders filed 30 SEC Form 4 transactions — 22 sales and 8 purchases. On net that is roughly 727K shares disposed (about $1.6M), a signal worth weighing alongside the fundamentals.

FLGT Financials

FLGT Latest News

FLGT Analyst Consensus

FLGT MoonshotScore

Fulgent Genetics, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources